Learn everything you need to know about Degarelix-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

*Localized: T 1/2, NX or N0, and M0. ‡ Locally advanced: T3/4, NX or N0, and M0, or N1 and M0. ITT: Intention to treat; PSA: Prostate-specific antigen. Reproduced ...

Review the side-effects of Degarelix as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

On-target activity of neoadjuvant cixutumumab and combined androgen deprivation therapy for high-risk prostate cancer: A phase II trial. Background: Degarelix, a GnRH receptor antagonist inducing ...

A head-to-head study comparing two types of androgen-deprivation therapy (ADT) for the treatment of prostate cancer showed there was no difference in the risk of major adverse cardiovascular events ...

Identifying enzalutamide resistance mechanisms in men with castration-resistant prostate cancer. Background: We hypothesize that the unmet drug development needs in prostate cancer can be addressed ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. The U.S. Department of Veterans Affairs (VA) has begun a clinical trial ...

A leading cancer surgeon has described Ferring's new prostate cancer drug degarelix, as a "breakthrough" on the basis of fresh Phase III results. A leading cancer surgeon has described Ferring’s new ...

We would like to update you on the decision made regarding the review of the existing guidance on TA404; Degarelix for treating advanced hormone-dependent prostate cancer. TA404 includes an optimised ...

Please provide your email address to receive an email when new articles are posted on . Men with prostate cancer assigned to degarelix had similar incidence of arrhythmia and less incidence of ...

CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...

Degarelix (Firmagon) is recommended as a possible treatment for advanced hormone-dependent prostate cancer in adults whose disease has spread to their spine. What does this mean for me? If you have ...